摘要
目的对晚期胃癌中β-微管蛋白Ⅲ表达与多西紫杉醇疗效关系进行研究。方法选取以多西紫杉醇方案为主要治疗方案的200例晚期胃癌患者为研究对象,检测其肿瘤组织中β-微管蛋白Ⅲ的表达情况,并对β-微管蛋白Ⅲ表达水平与患者的不良反应以及疗效进行分析。结果 200例晚期胃癌患者中,β-微管蛋白Ⅲ阳性患者的有效率低于β-微管蛋白Ⅲ阴性的患者,差异有统计学意义(P﹤0.05)。在治疗中消化道反应和骨髓抑制是最常见的不良反应,在给予患者对症治疗后,其耐受性良好,两组患者不良反应发生情况比较,差异无统计学意义(P﹥0.05)。结论β-微管蛋白Ⅲ表达情况可以作为以多西紫杉醇为主要治疗方案治疗晚期胃癌的疗效预测指标之一,但此结论还需更大样本临床研究证实。
Objective To explore the relation between the expression of β-tubulin Ⅲ and the efficacy of docetaxel in patients with advanced gastric cancer. Method 200 cases of patients with advanced gastric cancer who received docetax- el regimen as main treatment mode were selected. The expression of f3-tubulin Ⅲ in their cancer issues were tested, and the relation between the expression of β-tubulin Ⅲ and the rates of adverse reactions/efficacy was analyzed. Result In 200 cases of patients with advanced gastric cancer, the clinical efficacy rate of patients with β-tubulin III （＋） was less than that of patients with β-tubulin Ⅲ （-）, and the difference reached statistical significance （P〈0.05）. Gastrointestinal reac- tions and bone marrow depression were the most common adverse reactions during treatment. After symptomatic treat- ments were given, patient tolerance was acceptable and the differences in adverse reactions between two groups did not reach statistical significance （P〉0.05）. Conclusion The expression of β-tubulin Ⅲ can be used as a potential predic- tor of clinical efficacy of docetaxel regimen in patients with advanced gastric cancer who use it as the main treatment mode, but our conclusion needs to be verified by further clinical studies with a larger sample size.
出处
《癌症进展》
2017年第3期270-272,共3页
Oncology Progress
